Show simple item record

dc.contributor.authorCampion, Alicia*
dc.contributor.authorCasey, Patrick G.*
dc.contributor.authorField, Des*
dc.contributor.authorCotter, Paul D.*
dc.contributor.authorHill, Colin*
dc.contributor.authorRoss, R Paul*
dc.date.accessioned2013-05-21T15:32:38Z
dc.date.available2013-05-21T15:32:38Z
dc.date.issued01/02/2013
dc.identifier.citationAlicia Campion, Pat G Casey, Des Field, Paul D Cotter, Colin Hill and R Paul Ross. In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice. BMC Microbiology 2013, 13:23 doi:10.1186/1471-2180-13-23en_GB
dc.identifier.issn1471-2180
dc.identifier.urihttp://hdl.handle.net/11019/404
dc.descriptionpeer-reviewed
dc.description.abstractBackground: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo. Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model. More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen. Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.en_GB
dc.description.sponsorshipProgramme for Research in Third-Level Institutions (PRTLI); Irish Government under the National Development Plan; Irish Research Council for Science Engineering and Technology (IRCSET); Enterprise Ireland;Science Foundation Ireland (SFI), through the Alimentary Pharmabiotic Centre (APC) at University College Cork, Irelanden_GB
dc.language.isoenen_GB
dc.publisherBiomed Central
dc.relation.ispartofseriesBMC Microbiology;vol 13
dc.subjectAntimicrobial
dc.subjectLantibiotic
dc.subjectBacteriocin
dc.subjectPeptide engineering
dc.subjectMutagenesis
dc.subjectNisin
dc.titleIn vivo activity of Nisin A and Nisin V against Listeria monocytogenes in miceen_GB
dc.typeArticleen_GB
dc.identifier.rmisMDBY-0106-5271
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2180-13-23
dc.contributor.sponsorProgramme for Research in Third-Level Institutions
dc.contributor.sponsorIrish Research Council for Science, Engineering and Technology
dc.contributor.sponsorEnterprise Ireland
dc.contributor.sponsorScience Foundation Ireland
refterms.dateFOA2018-01-12T07:57:26Z


Files in this item

Thumbnail
Name:
1471-2180-13-23.pdf
Size:
835.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record